Tempest partners with Senlang to develop TPST-4003 in vivo CAR-T; IIT in China expected Q4 2026

Tempest Therapeutics, Inc.

Collaboration with Hebei Senlang Biotechnology for TPST-4003, a CD7-targeted in vivo CAR-T candidate.
First-in-human IIT in ~10 patients with myasthenia gravis or multiple sclerosis; first dosing Q4 2026.
Development fee range $1.5M-$2.0M per product; Senlang gets exclusive option for China rights.
Initial safety and PD data expected first half 2027.
Tempest retains all IP; Senlang will conduct trial in China.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.